Retatrutide Side Effects: What Early Clinical Trials Reveal

Retatrutide has generated significant attention as a potential next-generation weight-loss medication.

But alongside weight reduction outcomes, an equally important question remains:

What are the side effects?

Because retatrutide activates three hormonal pathways — GLP-1, GIP and glucagon — understanding its tolerability profile is essential.

Here’s what early clinical trials tell us so far.

Why Side Effects Occur with GLP-1–Based Medications

All medications in this class share a core mechanism:

They slow gastric emptying and suppress appetite.

This altered digestive signalling often leads to gastrointestinal symptoms, particularly during dose escalation.

To understand how this class works more broadly, see:
How Does Retatrutide Work? Understanding GLP-1, GIP and Glucagon

Most Commonly Reported Side Effects in Early Trials

In a 2023 Phase 2 trial published in The New England Journal of Medicine, retatrutide was evaluated in adults with obesity over 48 weeks.¹

The most commonly reported adverse events were:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Reduced appetite

• Abdominal discomfort

These effects were generally:

• Dose-dependent

• Most pronounced during titration

• Similar to other GLP-1 receptor agonists

Are Retatrutide Side Effects Worse Than Mounjaro or Ozempic?

Because retatrutide targets three receptors rather than one or two, researchers are closely monitoring whether:

• Gastrointestinal symptoms are more intense

• Discontinuation rates are higher

• Long-term tolerability differs

At present, data suggests side effects resemble those seen with semaglutide and tirzepatide, particularly at higher doses.¹

For comparison, you may find helpful:
Retatrutide vs Ozempic vs Mounjaro: What’s the Difference?

Appetite Suppression and Caloric Reduction

One of retatrutide’s primary effects is significant appetite suppression.

While beneficial for weight reduction, sustained reductions in calorie intake may influence:

• Meal frequency

• Protein intake

• Dietary fat intake

• Overall micronutrient exposure

This pattern is not unique to retatrutide — it is observed across GLP-1 medications.

To explore potential nutritional implications, see:
Nutrient Deficiencies Common on GLP-1 Medications (Mounjaro, Ozempic, Wegovy, Zepbound)

Does Retatrutide Affect Digestion Differently?

Like other GLP-1–based therapies, retatrutide slows gastric emptying.

Slower digestion can:

• Increase satiety

• Reduce portion sizes

• Alter eating patterns

While this supports weight loss, it may also influence digestive comfort, especially during early treatment phases.

For more on digestion and absorption, read:
How Do We Absorb Vitamins and Minerals?

Serious Adverse Events

In early clinical studies, serious adverse events were relatively uncommon, though monitoring continues.

As with other GLP-1 receptor agonists, clinicians remain attentive to:

• Pancreatitis risk

• Gallbladder disease

• Gastrointestinal intolerance

• Hypoglycaemia (particularly in combination therapies)

Long-term safety data is still developing, as retatrutide remains investigational.

Dose Matters

Higher doses in clinical trials were associated with:

• Greater weight reduction

• Higher rates of gastrointestinal side effects

This dose-response relationship is consistent with other medications in the class.

Gradual dose escalation is typically used to improve tolerability.

How Retatrutide Compares Mechanistically

Because retatrutide also activates glucagon receptors, researchers are evaluating whether this:

• Alters energy expenditure

• Influences liver metabolism

• Changes tolerability compared to dual agonists

For deeper mechanism insight, see:
What Is Retatrutide? The Science Behind the “Triple-G” Injection

FAQ: Retatrutide Side Effects

What are the most common side effects of retatrutide?

Nausea, vomiting, diarrhoea, constipation and reduced appetite are most frequently reported in early trials.

Are retatrutide side effects worse than Ozempic?

Current data suggests broadly similar gastrointestinal side effects, though long-term comparisons are ongoing.

Does retatrutide cause fatigue?

Fatigue has been reported with GLP-1 medications generally, though research continues to assess patterns with retatrutide.

Is retatrutide safe?

Retatrutide remains in clinical development. Larger and longer trials are required to establish full safety profiles.

Does appetite suppression affect nutrition?

Sustained appetite reduction may influence dietary intake and nutrient exposure over time.

For those concerned about vitamin depletion on GLP-1 drugs, this guide examines the current evidence.

Final Thoughts

Retatrutide’s early trial data suggests side effects similar to other GLP-1–based medications, particularly gastrointestinal symptoms during dose escalation.

Because it activates three hormonal pathways, ongoing research will clarify whether its tolerability differs meaningfully from existing therapies.

As with all emerging metabolic treatments, long-term safety and real-world data will be critical.

References

1. Jastreboff AM et al. Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526.

2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.

3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216.